Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s stock price was down 10.1% during mid-day trading on Tuesday . The stock traded as low as $1.12 and last traded at $1.16. Approximately 658 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 3,357 shares. The stock had previously closed at $1.29.
Vaccinex Price Performance
The stock has a fifty day moving average of $1.03 and a 200 day moving average of $1.06. The stock has a market cap of $3.02 million, a price-to-earnings ratio of -0.02 and a beta of 1.10.
Vaccinex Company Profile
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Featured Stories
- Five stocks we like better than Vaccinex
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
